首页 › 基金 › RTW INVESTMENTS, LP › VRDN
RTW INVESTMENTS, LP 对 VRDN 的持仓历史
VIRIDIAN THERAPEUTICS INC · 医疗保健
RTW INVESTMENTS, LP 在 Q3 2026 的 13F 申报中披露持有 VRDN(VIRIDIAN THERAPEUTICS INC)4,977,832 股,市值约 US$102.0M,约占其申报组合的 1.03%,在其申报持仓中市值排名第 36 位。 RTW INVESTMENTS, LP 最近 12 个申报季度中有 4 个季度披露了 VRDN 持仓,最早可追溯至 Q4 2023。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
RTW INVESTMENTS, LP 对 VRDN 的持仓演变
RTW INVESTMENTS, LP 于 Q4 2023 首次披露 VRDN 持仓:605,816 股(约 US$13.2M)。 该持仓在 Q3 2026 达到峰值 4,977,832 股,市值约 US$102.0M。 在 4 次申报中,RTW INVESTMENTS, LP 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 4,977,832 股、市值约 US$102.0M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2023 | 605.82K | $13.19M | 新进 |
| Q1 2024 | 605.82K | $10.61M | 持有 |
| Q2 2024 | 605.82K | $7.88M | 持有 |
| Q3 2026 | 4.98M | $102.03M | 新进 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 VRDN 与 13F 数据
VRDN(VIRIDIAN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 42 只申报持有 VRDN,申报仓位最大的包括:Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 VRDN 的基金
- Paradigm Biocapital Advisors LP 12.41M 股 · $227.08M · Q3 2026
- Kynam Capital Management, LP 6.15M 股 · $126.59M · Q3 2026
- Bellevue Group AG 6.73M 股 · $123.67M · Q2 2026
- Fairmount Funds Management LLC 5.09M 股 · $93.52M · Q2 2026
- Deep Track Capital, LP 3.83M 股 · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M 股 · $61.83M · Q3 2026
- Venrock Adviser, LLC 3.26M 股 · $59.85M · Q2 2026
- Context Capital Management, LLC 49.00M 股 · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M 股 · $51.48M · Q3 2026
- BAKER BROS. ADVISORS LP 2.38M 股 · $43.78M · Q2 2026
- Caligan Partners LP 2.19M 股 · $40.30M · Q2 2026
- Novo Holdings A/S 2.13M 股 · $39.22M · Q2 2026
更多关于 RTW INVESTMENTS, LP
常见问题
How long has RTW INVESTMENTS, LP held VRDN?
RTW INVESTMENTS, LP has disclosed VRDN holdings in 4 of the last 12 reported quarters, going back to Q4 2023.
What is RTW INVESTMENTS, LP's current position in VRDN?
As of Q3 2026, RTW INVESTMENTS, LP holds 4.98M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $102.03M, representing 1.03% of its reported portfolio and ranking #36.
Has RTW INVESTMENTS, LP been buying or selling VRDN?
In the latest 13F filing (Q3 2026), RTW INVESTMENTS, LP newly opened its position in VRDN. The position peaked in Q3 2026 at 4.98M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Bellevue Group AG, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.